What question did this study set out to answer?

To evaluate the efficacy and safety of subcutaneous isatuximab combined with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients who are transplant ineligible.

December 8, 2025BloodOpen Access

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

View Full Paper

Ask AI

Bookmark

Authors

RZRick Zhang TBThorsten Braun RTReza Tabrizi

Discussion

Member takes

Overview

Phase 2 trial showed high efficacy with ≥87.8% response rate in transplant ineligible multiple myeloma, indicating safety and improved convenience.

Key Points

To evaluate the efficacy and safety of subcutaneous isatuximab combined with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients who are transplant ineligible.
Prospective, multicenter, open-label, phase 2 study in NDMM TI patients aged ≥65 years.
Patients received isatuximab subcutaneously, along with bortezomib, lenalidomide, and dexamethasone over 12 cycles and followed by a maintenance phase.
Primary endpoint was the ≥very good partial response (VGPR) rate at 8 months.
The ≥VGPR rate was 87.8% (n=65) with a median follow-up of 11.7 months.
MRD negativity rates were 35.1% at 10⁻⁵ and 27% at 10⁻⁶.
No new safety signals observed; adverse events included infusion reactions in 9.5% of patients and neurological events in 47.3%.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df4c https://doi.org/10.1182/blood-2025-2275

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

View Full Paper

Ask AI

Bookmark

Authors

RZRick Zhang TBThorsten Braun RTReza Tabrizi

Discussion

Member takes

Overview

Phase 2 trial showed high efficacy with ≥87.8% response rate in transplant ineligible multiple myeloma, indicating safety and improved convenience.

Key Points

To evaluate the efficacy and safety of subcutaneous isatuximab combined with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients who are transplant ineligible.
Prospective, multicenter, open-label, phase 2 study in NDMM TI patients aged ≥65 years.
Patients received isatuximab subcutaneously, along with bortezomib, lenalidomide, and dexamethasone over 12 cycles and followed by a maintenance phase.
Primary endpoint was the ≥very good partial response (VGPR) rate at 8 months.
The ≥VGPR rate was 87.8% (n=65) with a median follow-up of 11.7 months.
MRD negativity rates were 35.1% at 10⁻⁵ and 27% at 10⁻⁶.
No new safety signals observed; adverse events included infusion reactions in 9.5% of patients and neurological events in 47.3%.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df4c https://doi.org/10.1182/blood-2025-2275

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark